Boxer Capital Management LLC Purchases New Shares in Inovio Pharmaceuticals, Inc. $INO

Boxer Capital Management LLC purchased a new position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,300,000 shares of the biopharmaceutical company’s stock, valued at approximately $5,382,000. Inovio Pharmaceuticals comprises approximately 1.7% of Boxer Capital Management LLC’s investment portfolio, making the stock its 15th biggest holding. Boxer Capital Management LLC owned approximately 3.45% of Inovio Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Inovio Pharmaceuticals by 35.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company’s stock worth $6,348,000 after buying an additional 703,727 shares in the last quarter. GSA Capital Partners LLP boosted its stake in shares of Inovio Pharmaceuticals by 171.4% in the 3rd quarter. GSA Capital Partners LLP now owns 443,104 shares of the biopharmaceutical company’s stock worth $1,037,000 after buying an additional 279,844 shares during the last quarter. Two Sigma Investments LP grew its holdings in shares of Inovio Pharmaceuticals by 299.9% in the third quarter. Two Sigma Investments LP now owns 290,800 shares of the biopharmaceutical company’s stock valued at $680,000 after acquiring an additional 218,073 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Inovio Pharmaceuticals in the second quarter valued at approximately $234,000. Finally, UBS Group AG increased its position in shares of Inovio Pharmaceuticals by 46.8% during the third quarter. UBS Group AG now owns 293,062 shares of the biopharmaceutical company’s stock valued at $686,000 after acquiring an additional 93,383 shares during the last quarter. 26.79% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on INO shares. HC Wainwright reissued a “neutral” rating on shares of Inovio Pharmaceuticals in a research report on Tuesday, December 30th. Oppenheimer reaffirmed an “outperform” rating on shares of Inovio Pharmaceuticals in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $6.75.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO opened at $1.66 on Friday. The stock has a market capitalization of $110.77 million, a PE ratio of -0.99 and a beta of 1.70. Inovio Pharmaceuticals, Inc. has a one year low of $1.30 and a one year high of $2.98. The business’s fifty day moving average price is $1.65 and its 200-day moving average price is $2.05.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.68. The firm had revenue of ($0.07) million during the quarter, compared to analysts’ expectations of $0.33 million. As a group, equities analysts expect that Inovio Pharmaceuticals, Inc. will post -4.23 EPS for the current fiscal year.

Trending Headlines about Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: BLA accepted under the FDA’s Accelerated Approval Program for INO‑3107 (potential RRP treatment); PDUFA date set for Oct. 30, 2026 — a clear regulatory milestone that could materially de‑risk and create commercial value if approved. INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Q4 2025 results showed a surprising EPS beat (reported $0.31 vs. consensus ~($0.37)), which reduces short‑term earnings uncertainty. The company also highlighted published clinical/immunology data and advancing next‑generation DNA medicine technologies (DMAbs, DPROT). INOVIO Reports Fourth Quarter and Full Year 2025
• Neutral Sentiment: Management discussed strategic moves and regulatory planning on the Q4 earnings call; investors should listen for commercialization plans, cash‑burn guidance, and timelines for INO‑3107 ahead of the October PDUFA. Earnings Call Highlights
• Negative Sentiment: Multiple law firms have filed or are soliciting lead‑plaintiff actions alleging securities fraud for the Oct. 10, 2023–Dec. 26, 2025 class period; several reminders cite an April 7, 2026 deadline — this legal overhang increases litigation risk, potential settlement exposure, and headline volatility. Representative notices: Glancy Prongay Wolke & Rotter and Schall Law Firm. Deadline Alert: Glancy Prongay Wolke & Rotter Schall Law Firm Notice
• Negative Sentiment: Revenue metrics missed expectations (press coverage shows revenue below consensus), and sell‑side models still forecast a negative FY EPS (analyst consensus cited ~‑4.23), implying continued cash‑flow and financing risk that could dilute shareholders. MarketBeat INO snapshot
• Negative Sentiment: Technical/market context: the 50‑day moving average sits below the 200‑day, and volume is below average — factors that can amplify downside during negative headlines. Interactive Chart

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.